Nxera Pharma Co., Ltd. (SOLTF) Comparison with companies in other sectors?

Nxera Pharma Co., Ltd. has a share price of 90.49M. You can analyze Nxera Pharma Co., Ltd. (SOLTF) competitors across different market sectors through stock heatmaps.

What are SOLTF's NET and operating margins?

Nxera Pharma Co., Ltd. (SOLTF) operating margin is around -0.27, and net profit margin is approximately -0.25 as of the latest reports.

In what way does SOLTF's earnings per share (EPS) trend reflect its financial momentum?

Nxera Pharma Co., Ltd. (SOLTF) EPS is -0.18 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Nxera Pharma Co., Ltd. is -35.50, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Nxera Pharma Co., Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Nxera Pharma Co., Ltd. like P/E which is -17.33, P/B which is 1.23, and PEG which is 0.02. Compare them with sector averages to evaluate if the stock is priced fairly.

Nxera Pharma Co., Ltd.

SOLTF•PNK

Healthcare

Biotechnology

$6.39

$0.24(3.90%)

Nxera Pharma Co., Ltd. (SOLTF) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.18

P/E Ratio

-35.50

ROE

-0.07%

Net Margin

-0.25%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$578.26M

Shares OutstandingTotal number of shares issued

$90.49M

Book Value/ShareNet worth per share

$769.35

Revenue/ShareAnnual revenue per share

$223.20

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.18

Net MarginNet income as percentage of revenue

-24.54%

Operating MarginOperating income as percentage of revenue

-27.25%

ROEReturn on shareholders' equity

-7.31%

ROAReturn on total assets

-3.14%

ROCEReturn on capital employed

-3.87%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$2.69

Cash/ShareCash and equivalents per share

$568.41

FCF YieldFree cash flow as percentage of market cap

0.28%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for SOLTFFinancial Ratios Analysis details for SOLTF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for SOLTFSector Benchmarking details for SOLTF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Nxera Pharma Co., Ltd. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Nxera Pharma Co., Ltd.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Nxera Pharma Co., Ltd.'s unique business strengths and challenges.

Key Financial Metrics for Nxera Pharma Co., Ltd.

For Nxera Pharma Co., Ltd., essential financial indicators include EPS -0.18, PE -35.50, and ROE -0.07. These key ratios reveal insights into Nxera Pharma Co., Ltd.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Nxera Pharma Co., Ltd. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Nxera Pharma Co., Ltd.

Metrics like Net Margin -24.54% and ROA -3.14% shed light on how well Nxera Pharma Co., Ltd. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Nxera Pharma Co., Ltd. can sustain its operations and continue growing in the future.

Valuation and Market Position of Nxera Pharma Co., Ltd.

Using ratios such as P/B Ratio 1.23 and PEG Ratio 0.02, investors can assess whether Nxera Pharma Co., Ltd. is appropriately valued based on its financials and growth potential. These figures, combined with Nxera Pharma Co., Ltd.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Nxera Pharma Co., Ltd.

Financial health indicators, such as Debt/Equity Ratio 1.03 and Cash Flow $2.69, provide a snapshot of Nxera Pharma Co., Ltd.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Nxera Pharma Co., Ltd., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Nxera Pharma Co., Ltd.

Investing in Nxera Pharma Co., Ltd. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Nxera Pharma Co., Ltd. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;